Prevalencia de injuria renal aguda en pacientes tratados con colistina

  • Liz Paola Martínez Gómez Universidad Nacional de Itapúa.
  • Edgar Ortega Filártiga Centro Médico Nacional.
Palabras clave: colistina, antibacterianos, infecciones por bacterias Gram negativas

Resumen

Introducción: la colistina es un antibiótico eficaz para tratar infecciones causadas por bacterias Gram negativas multirresistentes pero tiende a producir injuria renal aguda.

Objetivos: determinar la frecuencia de injuria renal aguda en pacientes adultos tratados con colistina e identificar la presencia de afecciones comórbidas asociadas.

Metodología: estudio observacional retrospectivo de pacientes tratados con colistina en el Hospital Nacional, Paraguay, en 2016-2017. 

Resultados: se estudiaron 80 pacientes, siendo 64% del sexo masculino. La edad media fue 50±17 años. La prevalencia de injuria renal aguda fue 70%. Según los criterios RIFLE hubo lesión en 45% de los casos, riesgo de lesión en 25% y no riesgo/no lesión en 30%. Las afecciones comórbidas más frecuentes fueron la hipertensión arterial (61%) y diabetes mellitus (31%). El germen aislado con mayor frecuencia fue Acinetobacter baumannii (57%), Pseudomonas aeruginosa (24%) y Klebsiella pneumoniae (19%). Los antibióticos más utilizados en forma combinada con la colistina fueron la vancomicina (46%) y los carbapenémicos (43%).

Conclusiones: la prevalencia de injuria renal aguda fue 70%. Según los criterios RIFLE predominó la lesión. Las afecciones comórbidas más frecuentes fueron la hipertensión arterial y la diabetes mellitus.

Biografía del autor

Liz Paola Martínez Gómez, Universidad Nacional de Itapúa.

Facultad de Medicina. Postgrado en Medicina Interna.

Edgar Ortega Filártiga, Centro Médico Nacional.

Hospital Nacional. Dpto. de Medicina Interna. Itauguá

Citas

1. Coria Lorenzo JJ, Morayta Ramírez A, Gutiérrez Muñoz Y. Polimixinas en la era de la multidrogorresistencia. Rev enferm infecc pediatr. 2011; 25(98):66-70.
2. Kaye KS, Pogue JM, Kaye D. Polymyxins (Polymyxin B and Colistin). In: Bennett JE, Dolin R, Blaser MJ, edited. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier 2015. p. 263-77.
3. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an old class of antibiotics. Future Microbiol. 2013; 8(6):711-24.
4. Vaara M. Novel derivatives of polymyxins. J Antimicrob Chemother. 2013;68(6):1213-9.
5. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al. Framework for optimization of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225-34.
6. Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiol. 2013; 79(2):200-8.
7. Fraimow H, Nahra R. Resistant gram-negative infections. Crit Care Clin. 2013; 29(4):895-21.
8. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010; 54(3):1117-24.
9. Gray JW, Mahida N. How do you solve a problem like multidrug-resistant Gram-negative bacteria? J Hosp Infect. 2016;92(1):1-2.
10. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother. 2007; 60:78-82.
11. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michaloupoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005; 8:24.
12. Caldeira Mendes CA, Burdmann EA. Polimixinas - revisão com ênfase na sua nefrotoxicidade. Rev Assoc Med Bras 2009; 55(6):752-9
13. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1:14.
14. Fica A, Céspedes J I, Gompertz M, Jalon M, Sakurada A, Sáez E. Colistín en infecciones nosocomiales por bacilos gramnegativos pan-resistentes. Rev Chil Infect. 2007; 24(5):360-7.
15. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese?. Clin Infect Dis. 2014; 59(1):88-94.
16. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014; 58(5):2740-6.
17. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010; 65:1019–27.
18. Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrugresistant gram-negative bacteria. J Infect. 2008; 56(3):185–90.
19. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd, Forrest A, Bulitta JB, Tsuji BT. Resurgenceof colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy, 2010;30:1279–91.
20. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1):1–12.
21. Molina J, Cordero E, Palomino J, Pachón J. Aminoglucósidos y polimixinas. Enf Infecc Microbiol Clin. 2009; 27:178–88.
22. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012; 18(1):18-29.
23. Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther. 2014 Jun;39(3):272-6.
24. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1:30.
25. Nilsson A, Goodwin RJ, Swales JG, Gallagher R, Shankaran H, Sathe A, et al. Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging. Chem Res Toxicol. 2015;28(9):1823-30.
26. Yun B, Azad MA, Wang J, Nation RL, Thompson PE, Roberts KD, Velkov T, Li J. Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother. 2015; 70(3):827-29.
27. Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57(12):6319-6324.
28. Dai C, Li J, Tang S, Kobayashi M, Yamada T, Iseki K. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother. 2014;58(7):4075-85.
29. Hoste EA, Kellum JA. Incidence, classification and results of acute renal injury. Contrib Nephrol. 2007; 156:32-8.
30. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109:c182-7.
31. Hoste EA, Clermontb G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill Patients: a cohort analysis. Crit Care. 2006;10(3): R73.
32. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, Antunes F, Prata MM. Prognostic utility of RIFLE for acute renal failure in patients with sepsis. Crit Care 2007;11(2):408.
33. Sirijatuphat R , Limmahakhun S , Sirivatanauksorn V , Nation RL , Li J , Thamlikitkul V . Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother. 2015;59(6):3224-32.
34. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015 Jul;71(7):801-10.
35. Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016; 60(4):2443–9.
36. Piccinni P, Cruz DN, Gramaticopolo S, Garzotto F, Dal Santo M, Aneloni G, et al. Prospective multicenter study on epidemiolog of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol. 2011; 77(11):1072-83.
37. Dalfino L, Puntillo F, Ondok MJ, Mosca A, Monno R, Coppolecchia S, et al. Colistin-associated acute kidney injury in severely lll patients: A step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015; 61(12): 1771–7.
38. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulfonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents. 2010; 35(3):297-300.
39. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009; 48(12):1724-8.
40. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors for colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34(5): 434-8.
41. Ortega-García MP, Abril-López de Medrano V, Gimeno Cardona C. Changes in the dosing of colistimethate sodium in critically ill patients. Rev Esp Quimioter. 2016;29(1):53–4.
42. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015. 14(11):1687-701.
43. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B?. Antimicrob Agents Chemother. 2017; 61(3):pii e02319-16.
44. Schneider AG, Uchino S, Bellomo R. Severe acute kidney injury not treated with renal replacement therapy: characteristics and outcome. Nephrol Dial Transplant. 2012 Mar;27(3):947-52.
45. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013; 57:1300–3.
46. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013;17(4):R174.
47. Durante-Mangoni E, Andini R, Signoriello S, Cavezza G, Murino P, Buono S, et al. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections. Clin Microbiol Infect. 2016 Dec;22(12):984-989.
48. Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol. 2009;47(9):3064-5.
Publicado
2018-09-01
Sección
ARTÍCULOS ORIGINALES